|drug2822||Passed infection of SARS-CoV-2 Wiki||0.58|
|D006330||Heart Defects, Congenital NIH||1.00|
|D018376||Cardiovascular Abnormalities NIH||0.58|
|D006331||Heart Diseases NIH||0.31|
There are 3 clinical trials
The ongoing Coronavirus (Covid-19) pandemic has recently generated the first epidemiological data on populations at risk. Currently, the risk factors, recognized for severe forms of Covid-19 infection, are elderly patients (> 70 years), obese patients, patients with chronic renal or respiratory diseases, cardiovascular history (stroke or coronary artery disease), high blood pressure, diabetes, and cancer. The population of congenital heart disease (CHD) might also be at risk, however, no data is available in this group of patients. CHD is the leading cause of birth defects, and as a result of recent medical advances, currently the number of adults with CHD exceeds the number of children, with an increasing prevalence of complex CHD. Approximately 200,000 children and 250,000 adults are living with a CHD in France today. The French Society of Cardiology, coordinator of this study, issued recommendations on March 14, 2020 for the French CHD population on the basis of expert opinions based essentially on the data published in the general population. Nevertheless, there is a need to provide scientific data on the impact of Covid-19 in the pediatric and adult CHD population. This study aims to assess the morbidity, the mortality and the risk factors associated with Covid-19 in patients with CHD in France
Description: Prevalence of Covid-19 infection in the overall CHD populationMeasure: Prevalence of Covid-19 infection in the overall CHD population Time: through study completion, an average of 2 weeks
Description: Prevalence of Covid-19 infection per CHD sub-groupMeasure: Prevalence of Covid-19 infection per CHD sub-group Time: through study completion, an average of 2 weeks
Description: Cardiovascular complicationsMeasure: Cardiovascular complications Time: through study completion, an average of 2 weeks
Description: Other complicationsMeasure: Other complications Time: through study completion, an average of 2 weeks
Description: Number of deathsMeasure: Number of deaths Time: through study completion, an average of 2 weeks
The study will analyze the prevalence of cardiac involvement of health care workers from the University Hospital of Salamanca (HUSA) who have overcome SARS-CoV-2 infection. Participants will undergo a clinical evaluation, electrocardiogram (EKG), cardiac magnetic resonance (CMR) and blood analysis including NT-proBNP, troponin, cellular and humoral immunity and genetics.
Description: Prevalence of myocardial damage suggestive of myocarditis assessed by cardiac magnetic resonanceMeasure: Myocarditis Time: up to 3 months
Description: Prevalence of pericarditis assessed by clinical criteriaMeasure: Pericarditis Time: up to 3 months
Description: Prevalence of atrial fibrillation on EKGMeasure: Atrial fibrillation Time: up to 3 months
Description: Prevalence of ischemic heart disease assessed by cardiac magnetic resonanceMeasure: Ischemic heart disease Time: up to 3 months
Description: Prevalence of dilatation of right heart chambers assessed by cardiac magnetic resonanceMeasure: Dilatation of right heart chambers Time: up to 3 months
Description: Prevalence of valvular heart disease assessed by cardiac magnetic resonanceMeasure: Valvular hear disease Time: up to 3 months
Description: Prevalence of prolonged QT interval on EKGMeasure: Rhythm disorders Time: up to 3 months
In this three-party collaboration, which includes The Texas Center for Pediatric and Congenital Heart Disease, the Value Institute for Health and Care, and the Design Institute for Health, all from University of Texas (UT) Dell Medical School, the investigators will explore how patient insights, data, storytelling, ideation, and prototyping can be employed to design a care delivery solution that enables patient outcome improvement. The goal of this project is to understand the life journey of patients with single-ventricle congenital heart disease and understand areas of that journey that can be improved. As such, the project intentionally does not start with a hypothesis, but instead seeks to gain insight of single-ventricle patients' care journey and based on that understanding identify opportunities for improvement.
Description: This is a qualitative research study. The investigators are using a combination of Experience Group sessions, Contextual Interviews and workshops with patients and their family members to obtain information to identify areas of the lifelong journey of patient with single-ventricle congenital heart disease and their families that can be redesigned to improve the outcomes that matter most to the patients and their familiesMeasure: Identification of areas to be improved in patient and families' journey Time: 2 years
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports